The cell and gene therapy contract development and manufacturing organization (CDMO) has completed its clinical capacity expansion in Alachua, Florida.
Brammer develops analytics and manufacturing processes for the major viral gene transfer vector systems at the facility and uses a range of production and purification platforms, including adherent and suspension up to 500L scale.
Additionally, Brammer installed an isolator and integrated fill line for drug product manufacturing in various forms.
In May of this year, the company also invested in its commercial-scale gene therapy manufacturing facility in Cambridge, MA. The facility is slated to open in the second half of the year. According to Brammer, it has invested more than $50m in capacity expansion in 2017.
The company currently has a team of 300 biopharmaceutical professionals with more than 160 based in Florida.